GSK

Forebygging på agendaen, hva er det vi venter på?

#News for #investors and #media: Today we announced that one of our investigational medicines has been granted SENKU designation by the Japanese Ministry of Health, Labour and Welfare (MHLW). Find out more https://gsk.to/3yVDq6d

#News for #investors and #media: Today we have announced that Japan has approved the use of one of our biologics as a treatment option for people with chronic rhinosinusitis and nasal polyps (#CRSwNP). Learn more here: https://gsk.to/3yWnj8o

Globally, health inequities are already hitting lower income countries hard. In 2015, loss of productivity due to preventable disease cost the African region $2.5 trillion. Health inequities are also the reason a 30-year life expectancy gap exists between populations in Japan and Lethoso, according to the World Bank. “The continual process of advancing health equity requires intentional action to address social determinants of health and reduce health disparities which benefits everyone,” says Dr Dolly White, program official at the National Institute on Minority Health and Health Disparities (NIMHD) in the US. Global biopharma companies, like GSK, are helping find solutions to health disparities by investing in collaborative programs that help to understand and eliminate barriers. Read more about our efforts to reduce the health equity gap – and why it’s so important – via our Behind the Science article here: https://gsk.to/46X26aW

100 years ago today, we launched Ostelin, the world’s first Vitamin D supplement. Step back to 1924 with us to discover the history of our first pharmaceutical product. In 1923, chief chemist Harry Jephcott heard of a new method of extracting Vitamin D from fish liver oils. Vitamin D was known to prevent rickets, which had become rampant in European cities from the late 1700s. Therefore, Jephcott decided that the creation of a Vitamin D supplement would support public health. By August 1924, Ostelin had been developed – for the first time it became possible to administer Vitamin D in doses, changing preventative healthcare forever. Since then, we’ve continued to uphold this legacy of prevention. Explore how it will remain at the forefront of our approach for years to come 👉 https://gsk.to/4cINYDw

As warming temperatures and extreme weather events exacerbate the spread of infectious diseases, maximising the role of vaccines can help mitigate the impact of climate change. In the face of disasters, such as the historic floods that submerged a third of Pakistan in 2022, for example, vaccines can provide critical protection. The deluge occurred during a high transmission season for polio, and vaccination infrastructure was mobilised to reach displaced communities. Thanks to these efforts, nearly 32 million children were vaccinated against the disease in August 2022. “We already have the tools, we just need to work out how to use them most effectively,” says Charlie Weller, Head of Prevention at Wellcome Trust and co-founder of the Coalition for Epidemic Preparedness Innovations. Find out more about the important, but often overlooked, role vaccines play here: https://gsk.to/4cJNPQs

In 2014, before vaccination programs had reached her rural enclave in Ethiopia, Asli tragically lost three of her young children – two to diarrhoea and one to measles. “We didn’t have vaccinations – there was no one to help them,” she tells us. “Before we had vaccinations, I used to worry about giving my children milk, food and water.” Thanks to collaborations with local actors, immunisation programs are now underway where Asli lives – a move that has brought her family great relief: “Now I feel happier for my children and I see the new, better health on their faces.” Our partnership with Save the Children UK has already transformed childhood access to immunisation in Nigeria and Ethiopia – but there is much more we can do. Here, Dr Teddy Gebremichael, Save the Children's Child Survival Advisor for the region, explains what needs to happen – and who we’re looking to empower – to bring new innovations to life: https://gsk.to/3YUxzZB

#News for #Investors and #Media: Today, we announced that the FDA has granted Breakthrough Therapy Designation to an investigational antibody-drug conjugate in our oncology portfolio. Learn more: https://gsk.to/3WR614w

“Covid was like a tsunami, it hit massively. It hit violently, and it washed over the world, but it will pass,” says Rob Bower, our former commercial lead on antibiotics. “AMR is like rising sea levels. It will keep rising. It will not stop, and suddenly we’ll be standing there with water around our knees.” The introduction of antibiotics in the 1940s extended people’s lives by an estimated 20 years. But if these medicines stop working, routine surgeries and cancer treatments, which can weaken the body’s ability to respond to infections, could become too risky. So, what do we need to do to stop this from happening? Here, experts from Dame Sally Davies to CARBX executive director Kevin Outterson, weigh in: https://lnkd.in/ertRtVgG

‘I began my career in healthcare more than 35 years ago, and I’ve never seen such huge potential for progress in the fight to prevent and treat disease as we have today,’ says Dr Chris Austin, the Senior Vice President of Research Technologies. And he’s right. Advances in data technology have allowed our scientists to make incredible new insights and drive forward drug discoveries. To continue to have real world impact, however, we need to ensure that our data is of the highest quality, accessible and always used with care. Read Dr Austin’s article here to find out why data scale, quality and responsibility is so important: https://gsk.to/3Aeinfl